TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

BACKGROUND: Taxane-platinum therapy (TP) has replaced platinum-based therapy (PC or PAC, DNA damaging chemotherapy) in the postoperative treatment of ovarian cancer patients; however, it is not always effective. TP53 protein plays a differential role in response to DNA-damaging agents and taxanes. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kupryjanczyk, Jolanta, Kraszewska, Ewa, Ziolkowska-Seta, Izabela, Madry, Radoslaw, Timorek, Agnieszka, Markowska, Janina, Stelmachow, Jerzy, Bidzinski, Mariusz
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268700/
https://www.ncbi.nlm.nih.gov/pubmed/18230133
http://dx.doi.org/10.1186/1471-2407-8-27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268700/
https://www.ncbi.nlm.nih.gov/pubmed/18230133
http://dx.doi.org/10.1186/1471-2407-8-27

Ejemplares similares